Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2019-01-07 Earnings Release
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
Earnings Release Classification · 85% confidence The document is a press release dated January 6, 2019, announcing the launch of a Phase 2a clinical study (NOVESA) for a drug candidate (GLPG1690) in patients with systemic sclerosis (SSc). It details the study design, endpoints, and provides background on the drug and the company (Galapagos NV). This type of announcement, focusing on clinical trial initiation, drug pipeline updates, and general corporate news, is characteristic of an Earnings Release (ER) or a general press release that doesn't fit a more specific financial filing category like 10-K or IR. Since it announces key operational and clinical progress rather than just financial results highlights (ER) or a formal regulatory filing, it aligns best with a general corporate announcement. However, given the options, announcements about clinical trial progress and pipeline updates are often categorized under Earnings Release (ER) if they accompany periodic results, or sometimes as Regulatory Filings (RNS) if they are standalone. Since this is a specific announcement about a clinical trial launch, and it is not a full financial report (10-K, IR) or a transcript (CT), it is most likely an Earnings Release (ER) if issued around a reporting period, or a general announcement. Given the context of a company providing updates on its pipeline and studies, ER is often used for such material news releases, even if not strictly quarterly results. If it were purely a regulatory filing without the press release structure, RNS would be considered. Since it is a detailed press release announcing a significant operational milestone (new study launch), ER is the closest fit among the provided options for material, non-financial-statement-focused news releases, although it could also be RNS. I will classify it as ER as it contains material information that would typically be discussed on an earnings call or in an accompanying release. Q1 2019
2019-01-07 English
Galapagos starts first Phase 1 trial with Toledo compound
Regulatory Filings Classification · 95% confidence The document is a press release dated January 7, 2019, announcing the initiation of a Phase 1 clinical trial for a new compound (GLPG3312) targeting an inflammation target class named 'Toledo'. It details the study design, provides background on the target, and includes standard forward-looking statements and contact information typical of corporate news releases regarding R&D progress. This type of announcement, focusing on clinical trial initiation and pipeline updates, is best classified as an Investor Presentation (IP) if it were a detailed deck, or more generally, a corporate announcement. Since it is a formal press release detailing scientific progress and pipeline status aimed at investors and the public, and it doesn't fit the specific definitions for ER (Earnings Release), AR (Audit Report), or CT (Call Transcript), it aligns most closely with the general category for investor-focused material that isn't a formal statutory filing. However, given the options, this is a specific corporate update about R&D progress. It is not a formal statutory filing like 10-K or IR. It is a press release announcing a significant operational milestone. In the context of the provided definitions, it is a specific corporate announcement. Since there isn't a dedicated 'Press Release' or 'R&D Update' category, and it is not a formal financial report, it falls under the general regulatory/corporate announcement category, RNS, or potentially IP if it were a presentation deck. Given the content is a news announcement about a clinical trial, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, as it is a formal communication to the market about a material event, but it is not a financial report itself. If we strictly interpret the definitions, it is a general corporate announcement. Let's re-evaluate against the definitions. It is not an ER (only highlights), not an IR (not comprehensive quarterly), not a CT. It is a specific operational update. RNS is the best fit for non-standard, material corporate announcements.
2019-01-07 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of January 2019. It references a press release dated January 4, 2019, attached as Exhibit 99.1. The document is short (2783 characters) and primarily serves to submit a press release rather than containing detailed financial data or a full report. Form 6-K filings are typically used by foreign private issuers to furnish reports or other documents required by their home country regulations or to provide information to the SEC. Given the nature of the document as a submission of a press release and not a full financial report or detailed filing, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-01-07 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of January 2019. It includes a press release as Exhibit 99.1 dated January 7, 2019. The document is only 2665 characters long, which is relatively short and primarily serves to submit a press release rather than containing detailed financial data or comprehensive reports. Form 6-K filings are typically used by foreign private issuers to furnish reports or documents that are required to be made public in their home country but are not annual or quarterly reports. Since this document is a Form 6-K with an attached press release and does not contain substantive financial statements or detailed report content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-01-07 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. It is described as a report pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 for the month of January 2019. The text indicates that the main content is a press release attached as Exhibit 99.1, which is incorporated by reference. The document itself is short (2665 characters) and primarily serves to submit the press release to the SEC. There is no substantive financial data or detailed report content within this filing. According to the rules, such a document that mainly attaches or references another report or press release and is short in length should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-01-07 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. It includes a press release as Exhibit 99.1 dated December 21, 2018. The document length is 2604 characters, which is relatively short and primarily serves as a report submission notice with an attached press release. There is no substantive financial data or detailed report content within this text. According to the rules, such filings that primarily serve to furnish a report or press release and are short in length should be classified as Regulatory Filings (RNS), as they do not constitute the full report themselves but rather a regulatory submission of information or announcement.
2018-12-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.